CLL1 and CD38 Dual-Target CAR-T Cell Injection
IIT2024059
Phase 1 small_molecule active
Quick answer
CLL1 and CD38 Dual-Target CAR-T Cell Injection for Acute Myeloid Leukemia is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active